Augmedix, Inc.: management transactions · United States · SEC (Form 4)

About Augmedix, Inc.

Augmedix, Inc. was a US healthcare technology company focused on ambient AI medical documentation. Before its acquisition, the stock traded on the NASDAQ under the ticker AUGX, and the company was headquartered in San Francisco, California, in the United States. Augmedix was incorporated in 2013 and launched commercial real-time remote documentation services in 2014. From an investor’s perspective, the company addressed a clear structural problem in healthcare: clinicians spending too much time on administrative documentation instead of patient care, especially in settings burdened by electronic health record workflows and labor shortages. Over time, Augmedix evolved from a remote scribe model into a broader documentation platform built around different levels of AI automation and human support. In 2024, the company said its business would focus on two core products, Augmedix Go and Augmedix Live. Augmedix Go is the more automated, AI-driven offering designed to draft clinical notes quickly, while Augmedix Live provides real-time documentation support through medical documentation specialists. The company also marketed hybrid configurations such as Augmedix Assist, allowing customers to choose the right balance between automation and human review. That flexibility was important because clinical workflows vary materially by specialty, care setting, and physician preference. Augmedix competed in the ambient AI and clinical documentation market against dictation software vendors, non-real-time note-generation tools, and other real-time medical scribe providers. Its competitive appeal lay in combining software, AI, workflow integration, and human operational support. The product set was built to integrate with customer EHR environments and serve hospitals, health systems, physician groups, and independent practices. Although the company’s commercial focus was primarily the United States, its operating footprint historically included international support centers, reflecting the labor-intensive nature of the service model. A major recent development was the acquisition by Commure. In July 2024, Augmedix announced that it would join forces with Commure, and on October 2, 2024, Commure completed the acquisition. At closing, Augmedix became a wholly owned subsidiary of Commure, and its shares ceased trading on the NASDAQ. For investors, this is the key context point: Augmedix is no longer an independently listed public equity, so historical SEC Form 4 insider transactions should be interpreted in light of the company’s transition from public market listing to private ownership. Nevertheless, the company remains a relevant case study in the commercialization of ambient AI for healthcare documentation and the consolidation of the sector.